Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized proof-of-concept study of talacotuzumab versus daratumumab in transfusion-dependent low-risk myelodysplastic syndromes after ESA failure
NL-OMON49651Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Talacotuzumab with Daratumumab (2 arms). Primary endpoints: 8-week red blood cell transfusion independence and Bayesian assessment of transfusion independence rate. Started Jul 2017; status: completed.
02
Drugs
talacotuzumabdaratumumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON49651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49651.